Showing 2781-2790 of 9932 results for "".
Exploring the Benefits of Nitric Oxide for Hair Loss Patients Through REVIAN® Red
https://practicaldermatology.com/topics/hair-nails/exploring-the-benefits-of-nitric-oxide-for-hair-loss-patients-through-revian-red/19753/Learn more about the mechanism of action of the new REVIAN Red Dual-Band LED light therapy cap and what makes it unique from other at-home FDA-cleared devices. REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton classifications of IIaOrchiectomy-Induced Melasma: Considering Melasma in Male Patients Post-Orchiectomy
https://practicaldermatology.com/topics/clinical-case-reports/orchiectomy-induced-melasma-considering-melasma-male-patients-post-orchiectomy/26663/Orchiectomy-Induced Melasma: Considering Melasma in Male Patients Post-OrchiectomyNoah Worcester 2024: Dr. Gold on Toxins
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-gold-toxins/24583/Noah Worcester 2024: Dr. Gold on ToxinsDermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourRepresentation in Marketing and Outreach
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/representation-in-marketing-and-outreach/19916/There is an apparent low rate of participation in aesthetic procedures among patients of color. Does this reflect a lack of interest or does limited representation in marketing and educational materials leave patients feeling that aesthetic interventions aren't meant for them? Panelists discuss theTaking the Leap Into Private Practice
https://practicaldermatology.com/programs/practical-dermatology/taking-the-leap-into-private-practice/24042/Practice is hard. Private practice is even harder.New in My Practice: Rx/New Products
https://practicaldermatology.com/columns/new-products/new-in-my-practice-rxnew-products-1/23636/New in My Practice: Cosmeceuticals
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-cosmeceuticals-3/23826/Galderma, Allergan Rosacea News, Dupilumab Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-allergan-rosacea-news-dupilumab-data/18591/Galderma Laboratories launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33. The FDA has accepted Allergan's New Drug Application (NDA) filing for oxymetazoline cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema assoUnify the United with Unity
https://practicaldermatology.com/topics/editorial/unify-united-unity/29187/Neal Bhatia, MD, Reflects on the nature of working together and unifying for the betterment of the dermatology profession.